Additional Verzenio® (abemaciclib) Phase 3 monarchE Trial Data Published in the Annals of Oncology

INDIANAPOLIS , Oct. 28, 2021 /PRNewswire/ -- Today, overall survival (OS) data from Eli Lilly and Company's (NYSE: LLY) Verzenio ® (abemaciclib) Phase 3 monarchE study were published in a Letter to the Editor in the Annals of Oncology . These OS data, while immature, have been published to address